Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender.
- People who have been diagnosed with myeloma and/or Plasma Cell Leukemia (confirmed by lab testing of tissue), who are newly diagnosed and have completed no more than one cycle of myeloma treatment.
- Women who could become pregnant must have a negative pregnancy test, or evidence of being post-menopausal (no periods for 24 months without another medical explanation), or have had a surgical procedure such as removal of both ovaries or the uterus.
- People who are willing to follow the birth control requirements set out in the trial, agree to take part in a safety program for the drug Lenalidomide, and sign a required agreement form.
- Men who agree to use a latex condom during any sexual intercourse for the entire duration of the study treatment, even if they have had a vasectomy.
- People who have recovered from side effects of any previous treatments, either back to their normal baseline or to a mild level, unless those side effects are considered minor or stable with supportive care (as determined by the treating doctor).
- People who are able to understand the study information and are willing to sign an approved consent form.
- People who are classified as "frail" based on a specific scoring system used by myeloma specialists (an IMWG frailty score of 3 or higher — the trial site can explain what this means in individual circumstances).
Who may not be able to join:
- People who are currently taking part in another clinical trial involving an experimental treatment.
- People who have any condition that, in the doctor's judgement, would affect their ability to understand the study information, give consent, or safely follow the study procedures — for example, active infection or inflammation, a blocked bowel, difficulty swallowing tablets (note: the study drug cannot be given through a feeding tube), or significant social or psychological concerns.
- People who have had a severe allergic reaction (grade 3 or higher on a standard medical scale) to the study drug or any of its ingredients, including steroids, mannitol, certain starches or salts, or other listed components, where that reaction could not be safely managed with pre-medications.
- People who are currently taking medications that are not permitted under the trial protocol.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ghulam Rehman Mohyuddin, MBBS, Huntsman Cancer Institute
Phone: 801-585-0115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Completion rate of 9 cycles of treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.